Final Draft Guidance News Today

 The National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance (FDG) recommending AQUIPTA® (atogepant), the oral, once-daily calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) as an option in suitable patients for preventing migraine i...

The National Institute for Health and Care Excellence (NICE) has issued guidance recommending GSK's Omjjara (momelotinib) as a treatment option for disease-related splenomegaly.

The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending empagliflozin (Jardiance®) as an option for the treatment of eligible adults with chronic kidney disease (CKD). 1 NICE has applied a streamlined process to this assessment of empagliflozin – an ...

NICE recommends Novartis Cosentyx® (secukinumab) as the first biologic treatment for hidradenitis suppurativa (HS) since 2016 •    Hidradenitis suppurativa (HS) is a painful, chronic and progressive inflammatory skin disease with over 50% of people reporting a mental health impact1,2 &bu...

Patients with a rare and incurable blood cancer, associated with an overproduction of blood cells, will soon have access to a small molecule Novartis treatment.

Daratumumab combination is recommended for use within the NHS in England and Wales for treating adults with newly diagnosed multiple myeloma where a stem cell transplant is unsuitableEligible patients throughout England and Wales can now access alternative combination treatment option which has been shown to delay d...

The National Institute for Health and Care Excellence (NICE) has recommended Idorsia UK’s QUVIVIQ (daridorexant) to treat chronic insomnia in adults.

The National Institute for Health and Care Excellence has published its Final Draft Guidance recommending the use of ruxolitinib as treatment for eligible patients in England and Wales with polycythemia vera that is resistant or intolerant to hydroxycarbamide/hydroxyurea.

The approved drug has been developed to treat patients with moderate to severe Crohn’s disease - News - PharmaTimes

UK's NICE issued its draft Final Appraisal Document (FAD) recommending the use of VAZKEPA (icosapent ethyl) in England and Wales to reduce the risk of cardiovascular (CV) events in adult statin-treated